JP2010529196A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529196A5
JP2010529196A5 JP2010512186A JP2010512186A JP2010529196A5 JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5 JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/007331 external-priority patent/WO2008156632A1/en
Publication of JP2010529196A publication Critical patent/JP2010529196A/ja
Publication of JP2010529196A5 publication Critical patent/JP2010529196A5/ja
Pending legal-status Critical Current

Links

JP2010512186A 2007-06-12 2008-06-12 アザペプチド誘導体 Pending JP2010529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Publications (2)

Publication Number Publication Date
JP2010529196A JP2010529196A (ja) 2010-08-26
JP2010529196A5 true JP2010529196A5 (cg-RX-API-DMAC7.html) 2011-08-04

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512186A Pending JP2010529196A (ja) 2007-06-12 2008-06-12 アザペプチド誘導体

Country Status (25)

Country Link
US (4) US20090036357A1 (cg-RX-API-DMAC7.html)
EP (3) EP2116532B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529196A (cg-RX-API-DMAC7.html)
KR (2) KR20120029480A (cg-RX-API-DMAC7.html)
CN (2) CN101711237B (cg-RX-API-DMAC7.html)
AR (1) AR066972A1 (cg-RX-API-DMAC7.html)
AT (2) ATE447554T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008267048C1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0813911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2692028C (cg-RX-API-DMAC7.html)
CO (1) CO6241121A2 (cg-RX-API-DMAC7.html)
CY (1) CY1109766T1 (cg-RX-API-DMAC7.html)
DE (1) DE602008000255D1 (cg-RX-API-DMAC7.html)
DK (1) DK2003120T3 (cg-RX-API-DMAC7.html)
ES (3) ES2356334T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100065T1 (cg-RX-API-DMAC7.html)
MX (1) MX2009013565A (cg-RX-API-DMAC7.html)
PL (1) PL2003120T3 (cg-RX-API-DMAC7.html)
PT (1) PT2003120E (cg-RX-API-DMAC7.html)
RS (1) RS51226B (cg-RX-API-DMAC7.html)
RU (2) RU2448958C2 (cg-RX-API-DMAC7.html)
SI (1) SI2003120T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908970A (cg-RX-API-DMAC7.html)
WO (1) WO2008156632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200909079B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241289A1 (en) * 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
RU2448958C2 (ru) * 2007-06-12 2012-04-27 Консерт Фармасьютикалз, Инк. Производные азапептидов
ES2574988T3 (es) * 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
EP2515877B1 (en) * 2009-12-21 2016-08-10 Janssen Sciences Ireland UC Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
BR112013031702B1 (pt) 2011-06-20 2021-11-03 H. Lundbeck A/S Composto 1-piperazino-3-fenil-indano deuterado, composição farmacêutica que o compreende e uso do referido composto ou da referida composição
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
PL3383397T3 (pl) * 2015-12-02 2021-12-27 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne zawierające dorawirynę, fumaran dizoproksylu tenofowiru i lamiwudynę
KR102744951B1 (ko) 2016-03-28 2024-12-23 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
ES3031110T3 (en) * 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN116033916A (zh) * 2020-04-16 2023-04-28 威斯康星州医药大学股份有限公司 用于治疗气道反流的hiv蛋白酶抑制剂气雾剂型制剂
CN114426568B (zh) * 2022-01-11 2023-04-25 嘉兴安谛康生物科技有限公司 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1314875C (en) 1985-05-15 1993-03-23 George Walter Koszalka Therapeutic nucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CA2605872A1 (en) 1992-12-29 1994-06-30 Abbott Laboratories Intermediates for retroviral protease inhibiting compounds
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
BR9507200A (pt) 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
MXPA03009971A (es) 2001-05-03 2004-02-12 Hoffmann La Roche FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ATE341332T1 (de) 2001-08-31 2006-10-15 Bristol Myers Squibb Co Verwendung von atazanavir in der hiv-therapie
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2676567A1 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
MXPA06015108A (es) * 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ugt1a1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
EP2059241A1 (en) 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
RU2448958C2 (ru) 2007-06-12 2012-04-27 Консерт Фармасьютикалз, Инк. Производные азапептидов
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Similar Documents

Publication Publication Date Title
JP2010529196A5 (cg-RX-API-DMAC7.html)
JP2012111758A5 (cg-RX-API-DMAC7.html)
JP2011510079A5 (cg-RX-API-DMAC7.html)
JP2012107057A5 (cg-RX-API-DMAC7.html)
JP2011518833A5 (cg-RX-API-DMAC7.html)
JP2006515626A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2007269812A5 (cg-RX-API-DMAC7.html)
JP2013532130A5 (cg-RX-API-DMAC7.html)
JP2009502793A5 (cg-RX-API-DMAC7.html)
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
JP2011508438A5 (cg-RX-API-DMAC7.html)
JP2010019854A5 (cg-RX-API-DMAC7.html)
JP2013500371A5 (cg-RX-API-DMAC7.html)
JP2008501714A5 (cg-RX-API-DMAC7.html)
JP2012514009A5 (cg-RX-API-DMAC7.html)
JP2009536652A5 (cg-RX-API-DMAC7.html)
JP2013014622A5 (cg-RX-API-DMAC7.html)
JP2013532687A5 (cg-RX-API-DMAC7.html)
JP2011519871A5 (cg-RX-API-DMAC7.html)
JP2008188757A5 (cg-RX-API-DMAC7.html)
JP2011037885A5 (cg-RX-API-DMAC7.html)
JP2010241791A5 (cg-RX-API-DMAC7.html)
JP2009249685A5 (cg-RX-API-DMAC7.html)
JP2011515327A5 (cg-RX-API-DMAC7.html)